Stock Movers

Stock Movers

By iHeartPodcastsNewsBusiness News
Download on the App Store
  • Favorites

    30

    Followers

  • Typical duration

    5 min

    per episode

Based on Podcast App listening data

Stock Movers episodes

  • Nvidia Rallies on Deal For AI Startup, Mining Stocks Soar, Tesla Slides

    On this episode of Stock Movers:

    - Nvidia (NVDA) agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. The world’s largest publicly traded company has paid for the right to use Groq’s technology and will integrate its chip design into future products. The deal was reported on after the end of the trading day on Christmas Eve. Shares of Nvidia rallied when trading resumed on Friday.

    - Shares of mining companies like Coeur (CDE) and Freeport (FCX) are higher in trading Friday as gold, silver and platinum jumped to all-time highs and copper surged to a record in Shanghai and rallied in New York. Spot gold rose as much as 1.2% to a peak above $4,530 an ounce on Friday. Spot silver for immediate delivery advanced for a fifth session, climbing as much as 5% to cross $75 an ounce.

    - Tesla (TSLA)'s ’s door handles are facing renewed scrutiny in the US after federal auto safety regulators opened a probe into the emergency releases in certain Model 3 vehicles. The National Highway Traffic Safety Administration said it’s evaluating claims that the mechanical door release “is hidden, unlabeled, and not intuitive to locate during an emergency,” according to a filing on the agency’s website. The move stems from a petition filed by Kevin Clouse, a Tesla owner in Georgia who says he was trapped in his vehicle in 2023 and requested a defect investigation. NHTSA said it hasn’t decided whether to grant or deny the petition. Shares of the Elon Musk-run EV maker fell in trading on Friday.

    See omnystudio.com/listener for privacy information.

    6 min
  • Nvidia Agrees to Groq Licensing Deal; India's Coforge Buys Encora; Biohaven Tumbles

    On this episode of Stock Movers:
    - Shares of Nvidia (NVDA) edge higher in the premarket session as the company agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products.
    - Shares of Indian technology services provider Coforge Ltd. (COFORGE IN) declined ahead of the US market open after the company agreed to buy Encora at an enterprise value of $2.35 billion in an all-stock deal, adding artificial intelligence, data and product engineering expertise. Encora’s shareholders, including Advent International and Warburg Pincus, will get about 20% stake in Coforge through a share swap. Coforge will issue 93.8 million shares at 1,815.91 rupees each to shareholders of Encora at equity value of $1.89 billion. The deal is expected to close in six months.
    - Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company’s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

    See omnystudio.com/listener for privacy information.

    5 min
  • Nvidia Edges Higher; Sidus Space Rallies; Biohaven Slips on Study

    On this episode of Stock Movers:
    - Shares of Nvidia (NVDA) edge higher in the premarket session as the company takes agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products.
    - Shares of Sidus Space (SIDU) rallied as much as 30 percent ahead of the US market open after the Cape Canaveral, Florida-based space and defense tech company announced plans to raise capital through a public offering of its Class A common stock and or pre-funded warrants.
    - Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company’s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

    See omnystudio.com/listener for privacy information.

    5 min
  • Nike Jumps, Costco Upgraded, Dynavax Soars

    - Nike (NKE) shares got a boost on Wednesday after a filing showed that Apple CEO Tim Cook purchased $2.95 million worth of shares on Dec. 22. Cook is Nike’s lead independent director and served as a director since 2005, according to the company’s website. The filing shows Cook purchased 50,000 Class B common stock at a weighted average price of $58.97.
    - Costco (COST) rose after receiving an upgrade for Christmas, as Northcoast Research analyst Charles Cerankosky raised the recommendation on wholesale giant to buy from neutral. His new price target of $1,100 implies a 29% increase from Tuesday's closing price. Investors who followed Cerankosky's recommendation received a 0% return in the past year, compared with a negative 9.5% return on the shares.
    - Dynavax (DVAX) popped after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.

    See omnystudio.com/listener for privacy information.

    4 min
  • Intel Falls, Dynavax Climbs, Snowflake Slides

    - Intel (INTC) shares fell Wednesday after a report said that Nvidia Corp. halted a test to use Intel’s production process to make advanced chips. Nvidia recently tested the so-called 18A process but stopped moving forward, Reuters reported, citing two unidentified people familiar with the matter. Spokespeople for Nvidia and Intel didn’t immediately respond to requests for comment. An Intel spokesperson told Reuters that the company’s 18A manufacturing technologies are “progressing well.”

    - Dynavax (DVAX) soared after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.


    - Snowflake (SNOW) dipped after The Information reported that the software company is in talks to buy the closely held Observe Inc. for around $1 billion. Baird writes that such a deal “could make strategic sense” as a way to compete with Databricks, which “has been very acquisitive to expand its platform.”

    See omnystudio.com/listener for privacy information.

    4 min
  • Intel Declines; Dynavax Rallies; Nike Ticks Higher

    On this episode of Stock Movers:
    - Shares of Intel (INTC) fell in the early session after Reuters reported that Nvidia halted a test that uses the chip manufacturer’s 18A technology to produce its chips. Nvidia recently tested whether it could manufacture its chips using Intel’s 18A production process but stopped moving forward, Reuters reported, citing two people familiar with the matter. Nvidia did not respond to Reuters’ request for comment, while an Intel spokesperson told Reuters the company’s 18A manufacturing technologies are “progressing well.”
    - Shares of Dynavax Technologies (DVAX) soared in premarket trading after Sanofi agreed to buy Dynavax for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.
    - Shares of Nike (NKE) moved higher ahead of the US market open after a filing shows that Apple CEO Tim Cook purchased $2.95 million worth of shares on December 22nd. Cook is Nike’s lead independent director and served as a director since 2005, according to the company’s website.

    See omnystudio.com/listener for privacy information.

    5 min
  • Dynavax Soars After Sanofi Acquistion; Intel Falls on Report; AST SpaceMobile Rallies

    On this episode of Stock Movers:
    - Shares of Dynavax Technologies (DVAX) soared in premarket trading after Sanofi agreed to buy Dynavax for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.
    - Shares of Intel (INTC) fell in the early session after Reuters reported that Nvidia halted a test that uses the chip manufacturer’s 18A technology to produce its chips. Nvidia recently tested whether it could manufacture its chips using Intel’s 18A production process but stopped moving forward, Reuters reported, citing two people familiar with the matter. Nvidia did not respond to Reuters’ request for comment, while an Intel spokesperson told Reuters the company’s 18A manufacturing technologies are “progressing well.”
    - Shares of AST SpaceMobile (ASTS) rallied ahead of the US market open after the company launched its largest-ever satellite from India, the first in a series of deployments to help AST compete against Elon Musk’s SpaceX in delivering space-based connectivity to mobile phones. The BlueBird 6 satellite took flight at 8:55 a.m. local time from the Satish Dhawan Space Center in southern India aboard the Indian Space Research Organization, or ISRO’s LVM3 rocket. The successful launch is a big boost for the Texas-based company as well as India’s space program which wants to build its orbital space station among other ambitious projects.

    See omnystudio.com/listener for privacy information.

    4 min
  • BP Spin Off, Abivax's 1600% Gains, B&M's Woes

    On This episode of Stock Movers:
    - BP agreed to sell a majority stake in its Castrol lubricants division to US investment firm Stonepeak Partners to raise about $6 billion.
    - French biotech company Abivax started the year with a market value of less than $500 million. After a meteoric rally, it’s now worth more than $8 billion — and some analysts see the potential for even more gains
    - B&M's stock has fallen 56% in 2025, extending the previous year’s 34% drop, as the firm struggles to contend with a cocktail of rising competition, increasing wage costs and a pinch on the low-income households that have been key to its past success.

    See omnystudio.com/listener for privacy information.

    5 min
  • BP Spin Off, Sanofi Down, Fresnillo Up

    On This episode of Stock Movers:
    - BP Plc agreed to sell a majority stake in its Castrol lubricants division to US investment firm Stonepeak Partners to raise about $6 billion.
    - Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as the French drugmaker tries to expand a vaccines business currently anchored by its flu shot franchise.
    - Fresnillo and other european mining stocks may be active on Wednesday as gold rises above $4,500 an ounce for the first time on escalating tensions in Venezuela and expectations for more US interest rate cuts. Silver, platinum and copper also hit records

    See omnystudio.com/listener for privacy information.

    5 min
  • Novo Nordisk Rallies, ServiceNow Dips, Sable Rises

    On this episode of Stock Movers:
    - Novo Nordisk (NVO) shares rallied in trading today following the drugmaker getting US approval to sell a pill version of its blockbuster obesity shot Wegovy. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. The pill is crucial for Novo’s strategy to take on Eli Lilly, which has said its own oral obesity drug could be approved by March. That would give Novo a head start of just a few months.
    - ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. The Santa Clara, California-based enterprise tech company will pay in cash for San Francisco-based Armis, according to a statement Tuesday that confirmed an earlier Bloomberg News report. ServiceNow, which provides software that helps companies organize and automate their personnel and information technology operations, has become a dominant platform for enterprise workflow. In March, ServiceNow struck an agreement to buy the artificial intelligence firm Moveworks Inc. for $2.85 billion as part of its push into AI tools that can complete tasks without human supervision. Shares of the startup fell during trading on Tuesday.
    - Sable (SOC) shares rose as much as 30% after the company said that the US Department of Transportation, Pipeline and Hazardous Materials Safety Administration approved the firm’s Las Flores pipeline restart plan.

    See omnystudio.com/listener for privacy information.

    7 min

About Stock Movers

From the publisher's feed

Listen for Short conversations on today's biggest winners and losers in the stock market. 

Best of Stock Movers

Ranked by our users in the last 21 days

More shows like Stock Movers

Bloomberg Intelligence by Bloomberg

Bloomberg Intelligence

403 Listeners

Bloomberg Surveillance by Bloomberg

Bloomberg Surveillance

1,159 Listeners

Masters in Business by Bloomberg

Masters in Business

2,176 Listeners

Odd Lots by Bloomberg

Odd Lots

1,973 Listeners

Bloomberg Businessweek by Bloomberg

Bloomberg Businessweek

422 Listeners

Wall Street Breakfast by Seeking Alpha

Wall Street Breakfast

1,033 Listeners

Thoughts on the Market by Morgan Stanley

Thoughts on the Market

1,298 Listeners

Here's Why by Bloomberg

Here's Why

61 Listeners

Wall Street Week by Bloomberg

Wall Street Week

61 Listeners

The Big Take by Bloomberg

The Big Take

154 Listeners

Bloomberg Daybreak: US Edition by Bloomberg

Bloomberg Daybreak: US Edition

88 Listeners

The Markets by Goldman Sachs

The Markets

85 Listeners

Bloomberg News Now by Bloomberg

Bloomberg News Now

72 Listeners

Bloomberg Daybreak: Asia Edition by Bloomberg

Bloomberg Daybreak: Asia Edition

8 Listeners

Bloomberg Daybreak: Europe Edition by Bloomberg

Bloomberg Daybreak: Europe Edition

9 Listeners